Valneva Stock Drops 2.34% and Extends Its Weekly Decline
The vaccine specialist's stock closed the session on Friday, October 17 at €4.346, down 2.34% from the previous day. This latest decline is part of a short-term negative trend that contrasts with an impressive performance over the year.
Recent Trading Session Overview
The decline observed this Friday was accompanied by a trading volume representing 0.31% of the capital, a moderate level indicating an activity without particular intensity. Over the past week, the correction has intensified with a cumulative loss of 9.65%, bringing the price below the symbolic threshold of €4.50. This consolidation phase comes after a spectacular increase of 57.81% over the last three months and 75.67% over the past year, performances significantly higher than the 9.11% recorded by the CAC 40 over the same period. The Paris market also ended slightly lower by 0.18% this Friday, reflecting a generally unencouraging context. This disconnect between the short-term trend and the substantial gains accumulated since the beginning of the year illustrates the volatility characterizing the stock. With a beta of 0.35, the stock shows limited sensitivity to market movements, suggesting that recent fluctuations are more likely due to company-specific factors than a close correlation with the benchmark index. Nevertheless, the monthly volatility, measured at 16.64%, remains high and indicates the range of variations that could occur in the short term.
Technical Analysis of the Stock
Technically, the stock is now in a delicate zone. It is slightly above its fifty-day moving average, set at €4.30, a level that traditionally serves as a reference for assessing the medium-term trend and whose immediate proximity may provide support in case of new selling pressure. The distance from the two-hundred-day moving average, positioned at €3.26, remains comfortable and confirms the solidity of the underlying bullish trend, although recent sessions somewhat nuance this view. The Relative Strength Index, at 56, remains in a neutral zone, signaling neither overbought nor oversold conditions, leaving room for various short-term scenarios. Momentum indicators provide mixed signals. The MACD, with a line at 0.11 slightly below its signal line at 0.18, produces a negative histogram of -0.06, indicating a weakening of the recent bullish momentum without clearly shifting to a bearish configuration. The Chaikin Money Flow, negative at -0.08, confirms a gradual withdrawal of buying flows over recent sessions. The Bollinger Bands, ranging between €4.08 and €5.12, frame the current price evolution and materialize a range within which the stock could continue to oscillate as long as no catalyst alters the balance between buyers and sellers.
Technical Support and Resistance Levels
The technical support level identified at €3.58 offers a safety margin of about 18% compared to the current price, while the resistance at €5.09 is now about 17% above the last quoted price. This symmetrical configuration reflects an intermediate positioning of the stock in its recent evolution channel. The Average True Range, measured at €0.15, reflects the average amplitude of daily variations and allows for anticipation of potential movements within this range. The succession of closing declines over the last five sessions, visible in the weekly historical data, illustrates persistent selling pressure that has not yet challenged the major support levels identified by the graphical analysis.
